Astellas Pharma: Astellas Pharma has received a positive opinion from the CHMP for the combination of PADCEV and KEYTRUDA as the first-line treatment for advanced bladder cancer.

JPX · Jul 29 07:30

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.